- Home
- HSDT vs PRFX Comparison
HSDT vs PRFX Comparison
Compare HSDT & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSDT
- PRFX
- Stock Information
- Founded
- HSDT N/A
- PRFX 2007
- Country
- HSDT United States
- PRFX Israel
- Employees
- HSDT N/A
- PRFX N/A
- Industry
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- HSDT Health Care
- PRFX Health Care
- Exchange
- HSDT Nasdaq
- PRFX Nasdaq
- Market Cap
- HSDT 2.5M
- PRFX 2.9M
- IPO Year
- HSDT N/A
- PRFX 2020
- Fundamental
- Price
- HSDT $7.71
- PRFX $1.49
- Analyst Decision
- HSDT Hold
- PRFX Hold
- Analyst Count
- HSDT 1
- PRFX 1
- Target Price
- HSDT N/A
- PRFX N/A
- AVG Volume (30 Days)
- HSDT 200.4K
- PRFX 338.2K
- Earning Date
- HSDT 08-11-2025
- PRFX 08-14-2025
- Dividend Yield
- HSDT N/A
- PRFX N/A
- EPS Growth
- HSDT N/A
- PRFX N/A
- EPS
- HSDT N/A
- PRFX N/A
- Revenue
- HSDT $434,000.00
- PRFX N/A
- Revenue This Year
- HSDT N/A
- PRFX N/A
- Revenue Next Year
- HSDT $75.13
- PRFX N/A
- P/E Ratio
- HSDT N/A
- PRFX N/A
- Revenue Growth
- HSDT N/A
- PRFX N/A
- 52 Week Low
- HSDT $7.15
- PRFX $1.25
- 52 Week High
- HSDT $1,200.00
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- HSDT 21.56
- PRFX 43.85
- Support Level
- HSDT $7.15
- PRFX $1.25
- Resistance Level
- HSDT $8.78
- PRFX $1.44
- Average True Range (ATR)
- HSDT 1.37
- PRFX 0.11
- MACD
- HSDT 6.59
- PRFX 0.02
- Stochastic Oscillator
- HSDT 4.65
- PRFX 77.42
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.